Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) hit a new 52-week high during trading on Thursday . The stock traded as high as $16.98 and last traded at $16.61, with a volume of 512,813 shares changing hands. The stock had previously closed at $16.22.

LXRX has been the subject of several recent analyst reports. Cowen and Company reaffirmed a “market perform” rating on shares of Lexicon Pharmaceuticals in a research note on Tuesday, May 3rd. Needham & Company LLC reaffirmed a “buy” rating and issued a $21.00 target price on shares of Lexicon Pharmaceuticals in a research note on Wednesday, May 4th. JPMorgan Chase & Co. reaffirmed a “hold” rating and issued a $16.00 target price on shares of Lexicon Pharmaceuticals in a research note on Thursday, May 5th. Wedbush reaffirmed an “outperform” rating and issued a $28.00 target price on shares of Lexicon Pharmaceuticals in a research note on Friday, May 6th. Finally, Zacks Investment Research downgraded shares of Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, May 6th. One analyst has rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating to the company. The company has an average rating of “Hold” and a consensus price target of $18.50.

The stock has a 50 day moving average of $14.50 and a 200 day moving average of $12.44. The company’s market capitalization is $1.71 billion.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last announced its quarterly earnings results on Tuesday, May 3rd. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by $0.04. During the same quarter in the previous year, the business earned ($0.04) earnings per share. The company had revenue of $12.50 million for the quarter, compared to the consensus estimate of $11.11 million. The company’s revenue was up 594.4% compared to the same quarter last year. On average, analysts expect that Lexicon Pharmaceuticals Inc. will post ($1.55) EPS for the current fiscal year.

In related news, VP James F. Tessmer sold 6,000 shares of Lexicon Pharmaceuticals stock in a transaction that occurred on Monday, May 23rd. The shares were sold at an average price of $13.00, for a total transaction of $78,000.00. Following the sale, the vice president now directly owns 21,946 shares in the company, valued at approximately $285,298. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

A number of large investors have bought and sold shares of the company. Nationwide Fund Advisors increased its stake in Lexicon Pharmaceuticals by 124.1% in the fourth quarter. Nationwide Fund Advisors now owns 139,876 shares of the biopharmaceutical company’s stock valued at $1,862,000 after buying an additional 77,446 shares in the last quarter. California State Teachers Retirement System increased its stake in Lexicon Pharmaceuticals by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 76,947 shares of the biopharmaceutical company’s stock valued at $1,024,000 after buying an additional 1,372 shares in the last quarter. ProShare Advisors LLC increased its stake in Lexicon Pharmaceuticals by 7.7% in the fourth quarter. ProShare Advisors LLC now owns 89,382 shares of the biopharmaceutical company’s stock valued at $1,190,000 after buying an additional 6,390 shares in the last quarter. Finally, New York State Common Retirement Fund increased its stake in Lexicon Pharmaceuticals by 240.2% in the fourth quarter. New York State Common Retirement Fund now owns 177,168 shares of the biopharmaceutical company’s stock valued at $2,358,000 after buying an additional 125,083 shares in the last quarter.

Lexicon Pharmaceuticals, Inc (Lexicon) is a biopharmaceutical company. The Company focuses on the development of treatments for human disease. The Company is engaged in the development of two drug candidates: telotristat etiprate (LX1032) and sotagliflozin (LX4211). The Company’s telotristat etiprate, is an orally delivered small molecule drug candidate, as a treatment for carcinoid syndrome.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.